Assessing Clinical Outcomes in Alzheimer's Disease Agitation

计划入组 178 人 · 首次发布于 2021 年 3 月 15 日

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

计划入组 408 人 · 首次发布于 2022 年 9 月 28 日

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

计划入组 456 人 · 首次发布于 2021 年 7 月 1 日

Alzheimer's disease(Abarceo)

Alzheimer's disease (Precisionlife)

Alzheimer's disease(CuroNZ)

Alzheimer's Disease And Related Disorders Association, Inc.

United States

Alzheimer's Disease And Related Disorders Association, Georgia Chapter, Inc.

United States

Alzheimer's Light, LLC

United States

FDA Approves Auvelity for Alzheimer's Disease Agitation, Marking Second Approved Treatment Option

Axsome's AXS-05 Shows Promise in Alzheimer's Agitation Trials, NDA Submission Planned for 2025

Axsome Therapeutics Receives FDA Priority Review for AXS-05 in Alzheimer's Disease Agitation